Sarah Yim said extensive research helped convince hesitant colleagues that comparative clinical trials were not needed for insulin biosimilars. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
